Bexxar治疗非霍奇金淋巴瘤的研究现状  

Current status of Bexxar for treatment of non-Hodgkin's lymphoma

作　　者：陈立波[1] 朱瑞森[1] 

机构地区：[1]上海交通大学附属第六人民医院核医学科,200233

出　　处：《国外医学（放射医学核医学分册）》2005年第2期67-70,共4页Foreign Medical Sciences(Section of Radiation Medicine and Nuclear Medicine)

摘　　要：B细胞靶向特异性单克隆抗体的出现为惰性淋巴瘤的治疗提供了新的策略。由于淋巴瘤对辐射较为敏感,在过去的10年中,应用131I标记抗鄄CD20单克隆抗体(商品名:Bexxar)对化疗无效的非霍奇金淋巴瘤(NHL)患者进行放射免疫治疗取得了长足的发展。Immunotherapy using monoclonal antibodies to specifically target B cells has provided new strategy to many patients with indolent lymphomas. Lymphomas are extremely sensitive to radiation, and significant progress has been made over the last decade in the development of radioimmunotherapy with 131I labeled anti-CD20 antibodies(Bexxar).

关 键 词：非霍奇金淋巴瘤 抗-CD20抗体 碘放射性同位素 放射免疫治疗 

分 类 号：R733.1[医药卫生—肿瘤]